OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC)

Abstract only

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 29; no. 15_suppl; p. LBA5007
Main Authors Aghajanian, C., Finkler, N. J., Rutherford, T., Smith, D. A., Yi, J., Parmar, H., Nycum, L. R., Sovak, M. A.
Format Journal Article
LanguageEnglish
Published 20.05.2011
Online AccessGet full text

Cover

More Information
Summary:Abstract only
ISSN:0732-183X
1527-7755
DOI:10.1200/jco.2011.29.15_suppl.lba5007